论文部分内容阅读
应用免疫组织化学方法检测80例乳腺癌的nm23—H_1基因和组织蛋白酶D(Cath-D)表达,结果发现:无瘤生存组此两指标的阳性表达分别为68.4％(39/57)和31.6％(18/57);复发死亡组分别为30.4％(7/23)和95.6％(22/23);此两指标与淋巴结转移无显著关系,但nm23-H_1基因阳性而Cath-D阴性的乳腺癌,淋巴结转移阳性率高,预后差。结果提示nm23-H_1基因和Cath-D联合分析能更好地判断乳腺癌的转移和预后。
Immunohistochemistry was used to detect the expression of nm23-H_1 gene and cathepsin D (Cath-D) in 80 cases of breast cancer. The results showed that the positive expression of the two indicators in the tumor-free survival group was 68.4% (39/57) and 31.6 respectively. % (18/57); Recurrence of death group was 30.4% (7/23) and 95.6% (22/23) respectively; these two indicators had no significant relationship with lymph node metastasis, but nm23-H_1 positive and Cath-D negative The positive rate of breast cancer and lymph node metastasis is high and the prognosis is poor. The results suggest that the joint analysis of nm23-H_1 gene and Cath-D can better determine the metastasis and prognosis of breast cancer.